Kymera Therapeutics, Inc. (KYMR)
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
$115.43-0.89%
Close 2026-09-09 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
Intact: The reason to own it still holds.
Kymera grew revenue from $2.76M to $34.37M in nine months. It has $1.6B cash to fund work through 2029. Operating losses improved from -$97.9M to -$84.15M in the last quarter. The company is advancing clinical programs to grow sales.
Kymera is still losing a lot of money. Revenue is expected to fall 14% next year. The company missed earnings several times last year. Cash could run low if losses don't improve.
The price is about 4% below our fair value near $124. Analysts expect revenue to fall about 14% next year. Our fair value matches the Street median.
Breaks if: Cash falls below $1 billion before 2029
Continue to preserve a strong cash balance with runway into 2029 to support operations and development programs.
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity. The current thesis state is cautious, as the company is navigating a fragile earnings quality while attempting to advance its clinical developments.
The market appears to price in a significant expectations gap, suggesting that investors may not fully account for the company's fragile execution. Valuation shows a premium compared to peers, indicating that some optimism is already embedded in the stock.
Fundamentals are expected to remain mixed as management works on advancing clinical trials while maintaining a strong cash position. Recent performance has improved, but the overall earnings quality remains fragile, which could impact future results.
The thesis hinges on how management communicates future guidance and the performance of sector bellwethers. Additionally, macroeconomic factors like job market trends could influence investor sentiment and the company's performance.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The latest earnings beat supports this improved outlook. There are no new threats identified that would weaken the thesis.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: Operating losses worsen beyond -$100 million next quarter
Breaks if: Revenue falls below $20 million next quarter
In the next 1-3 years, KYMR's trajectory will depend on its clinical advancements and the broader healthcare sector's performance. Not investment advice.